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ABSTRACT
Sarcopenia is a disorder of progressive loss of skeletal muscle mass and strength that is linked with multiple 
complications, decreased physical activity, lower quality of life and accelerated mortality rate. It is more common 
among cancer patients and identified with reduced tolerance by the toxic effects from cancer therapy, negative 
outcomes, lowered response and overall survival rate. This narrative review aims to demonstrate the dual impact 
from the co-occurrence of cancer therapy; chemotherapy, radiotherapy, immunotherapy, and sarcopenia alongside 
the potential complications from their coincide effects on cancer prognosis. By searching through data sets, all 
articles that focused on sarcopenia and cancer therapy were collected in the indexed journals between the years 
2000 and 2021 that could provide findings for the potential complications from the coinciding effects of cancer 
therapy and sarcopenia in cancer patients receiving chemo-radio- and immunotherapy. Outcome measures were 
the rate of studies showing potential complications from the co-occurrence of cancer therapies and sarcopenia. 
A total of hundred-two cohort studies were enrolled. The majority were about chemotherapy and sarcopenia (45%). 
About 56.9 % of the studies designed as retrospective analysis, and a high proportion were about chemotherapy 
and sarcopenia (21.6%). About 63.7% of the studies reported skeletal muscle index as the primary marker. Lower 
than half of the reviewed studies revealed a significant increase in the rate of sarcopenia (47%). The direct toxic 
effects of chemotherapy on skeletal muscle were reported in 13.7% of the studies. Studies that reported the 
impact of sarcopenia on a reduction in chemotherapy cycles were about 10.8%. About 11.8% and 14.7% of the 
studies showed lowered overall survival by the coinciding impact of chemotherapy/radiotherapy and sarcopenia, 
respectively. In conclusion, the evaluation of sarcopenia in cancer patients should be considered a primary part of 
oncological care in cancer patients as there are potential complications and poor survival from the co-occurrence 
of sarcopenia and different cancer therapies.  
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Introduction
Sarcopenia term first took its place in medical 
literature in the late 1980s by Rosenberg and consists 
of two words: “sarx (muscle)” and “penia (loss)”. It is 
defined as a progressive generalized loss of muscle mass 
and strength as a secondary complication to chronic 
disease conditions, sedentary lifestyle, and malnutrition 
[1–3]. Sarcopenia is strictly correlated with increased 
risk of functional impairment, disability, physical in-
sufficiency, falls and fractures, low quality of life, poor 
patient outcomes, and a high rate of mortality [3]. It is 
categorised into three stages based on the definition of 
the European Working Group on Sarcopenia in Older 
People (EWGSOP). A pre-sarcopenia stage is charac-
terized by a decrease in muscle mass. This stage does 
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not affect muscle strength and physical performance 
and can be identified by accurate measuring of muscle 
mass. A sarcopenia phase is manifested by a decrease 
in muscle mass, strength, or physical performance. 
In severe sarcopenia, there is an obvious decrease in 
muscle mass, strength, and physical performance [4, 5]. 
In sarcopenia, potential components for loss of 
muscle quality, mass, and strength include a diminished 
skeletal muscle innervation and capillary density and 
the specific decay of type II muscle filaments; that is, 
a decrease in the motor units involved in the binding 
of neurons and muscle fibres [6]. The immediate result 
of sarcopenia is the loss of skeletal muscles, which are 
not just an essential piece of the motor system but 
also, modulate immune and inflammatory processes 
by secreting multiple cytokines, such as tissue necrosis 
factor-a (TNF) to promote systemic inflammation. 
Along these lines, sarcopenia may bring down natural 
killer (NK) cells in cancer patients, thereby debilitating 
the anti-tumour immune response and worsening pa-
tient prognosis [7–9]. Myokines, like interleukin (IL)-6, 
can have anti-tumorigenic impacts by interacting with 
NK cells and actuating the production of IL-1 receptor 
antagonist and IL-10 by the molecules with anti-in-
flammatory effects [10, 11]. On the other hand, the 
pro-inflammatory factors delivered by both immune cells 
and tumour cells advance muscle tissue disintegration 
and restrain skeletal muscle cell differentiation which 
can inhibit protein synthesis and muscle regeneration, 
ultimately prompting muscle atrophy [12]. Besides, 
TNF-a can straightforwardly instigate muscle atrophy 
through the ubiquitin-proteasome system (UPS) [13]. 
Furthermore, many risk factors are associated with 
the development of sarcopenia. They include age-related 
changes in tissue secretion or responsiveness to trophic 
hormonal factors, nutritional insufficiency, a diet poor in 
protein, muscle fibre count, genetic factors, immobility, 
post-traumatic, smoking, alcohol, sedentary lifestyle and 
acute and chronic co-morbid disease conditions such 
as obesity, osteoporosis and type 2 diabetes mellitus, 
insulin resistance and underlying malignancy [14, 15]. 
This narrative review aims to demonstrate the bi-
modal impact from the co-occurrence of cancer therapy; 
chemotherapy, radiotherapy, immunotherapy, and 
sarcopenia alongside the potential complications from 
their coincide effects on cancer prognosis. 
Methods 
Search and data extraction
By searching through data sets within PubMed, 
Google Scholar, ISI, Scopus, and Embase, all articles 
that focused on sarcopenia and cancer therapy were 
gathered in the indexed journals between the years 
2000 and 2021 that could provide information on the 
correlated effects of different therapeutic agents used 
in cancer therapy and sarcopenia. The search strategy 
for this study was performed utilizing the terms of medi-
cal subject headings (MeSH) and combinations of the 
keywords according to the following: sarcopenia, cancer, 
chemotherapy, radiotherapy, chemo-radiotherapy, im-
munotherapy, immune checkpoint inhibitors, skeletal 
muscle, and body mass index. Inclusion criteria were 
all articles that focused on the co-existence of cancer 
therapy and sarcopenia regarding the potential impact 
of cancer therapy (chemo-radio-and immunotherapy)-
induced toxicity on the incidence and prognosis of sarco-
penia and vice versa. These included randomised clinical 
trials, case-control, and retrospective studies; while the 
titles, abstracts, and full texts of all imported studies 
were screened by the researchers. Data were extracted 
from included studies for the following evidence: author, 
country, year of publication, type of study, sample size, 
cancer type, cancer therapy, duration of therapy in days, 
body composition marker, rate of sarcopenia evalua-
tion, and summary of main outcomes. The accuracy and 
quality of the included data were additionally checked 
and the review process excluded irrelevant studies and 
articles, and those not in the English language (Fig. 1).
Records identified through 
database searching





based on the title 
and abstract












included in review study
n = 102
Figure 1. Flowchart for the database searching and articles 
selection
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Table 1. Summary of findings for the reviewed cohort studies 
Variable Number 
of Reviewed Studies 
(n = 102)
Percentage
Studies-related cancer therapy 
    Chemotherapy 46 45.0
    Chemo-radiotherapy 28 27.5
    Immunotherapy 28 27.5
Study design 
    Retrospective 58 56.9
    Prospective 44 43.1
Cancer diagnosis
    Oesophagogastric carcinoma 14 13.7
    Non-small cell lung carcinoma (NSCLC) 15 14.7
Anticancer therapy 
    Platinum-based compounds 14 13.7
    Pembrolizumab 16 15.7
    Nivolumab 16 15.7
Surrogate for skeletal muscle mass
    Skeletal muscle index (Total) 65 63.7
    Skeletal muscle index (chemotherapy) 29 44.6
    Skeletal muscle index (chemo-radiotherapy) 18 27.7
    Skeletal muscle index (immunotherapy) 18 27.7
Rate of sarcopenia 48 47
Impact of chemotherapy on sarcopenia incidence 14 13.7
Impact of sarcopenia on administration of chemotherapy schedules 11 10.8
Lowered overall survival by coincide impact of chemotherapy and sarcopenia 12 11.8
Lowered overall survival by coincide impact of radiotherapy and sarcopenia 15 14.7
Impact of sarcopenia on administration of immunotherapy schedules 8 7.8
Overall Outcome* 95 93.1
Data presented as number (n) and percentage (%); *A significant negative impact to the co-existence of sarcopenia and cancer therapy
Results
A review of hundred-two cohort studies conducted 
on the potential complications from coinciding effects of 
cancer therapy and sarcopenia in cancer patients receiv-
ing chemo-radio- and immunotherapy revealed varied 
results. Most of the reviewed studies were about the 
potential impact of cancer chemotherapy and sarcopenia 
(45%) (Tab. 1 and 2); while an equal proportion of the 
reviewed studies was about the impact of sarcopenia in 
chemo-radiotherapy and immunotherapy (27.5%), as 
shown in Tables 1, 3 and 4. 
The present study showed that a total of 58 stud-
ies (56.9%) were designed as retrospective analyses, 
and a high proportion of these retrospective stud-
ies was about cancer chemotherapy and sarcopenia 
(n = 22) (Tab. 1 and 2). Nearly an equal proportion of 
the reviewed studies were conducted among patients 
who suffered from oesophagogastric carcinoma re-
ceived chemotherapy and non-small cell lung cancer 
patients received immunotherapy (NSCLC) (13.7%, 
14.7%), respectively (Tab. 1, 3 and 4). Furthermore, 
platinum-based compounds represented the most 
common chemotherapeutic agents administered within 
the scope of chemotherapy and sarcopenia (13.7%) 
(Tab. 1 and 2); while both pembrolizumab and nivolum-
ab represented the most common immune checkpoint 
inhibitors (15.7%) administered within the scope of 
immunotherapy and sarcopenia, as shown in Tables 1, 
3 and 4. 
Regarding the marker of body composition (a sur-
rogate for skeletal muscle mass), skeletal muscle index 
4
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was the high-ranked marker among the reviewed studies 
(63.7%), as following: chemotherapy (44.6%) and equal 
proportion for chemo-radiotherapy and immunotherapy 
(27.7%). The present study also showed that lower 
than half of the reviewed studies revealed a significant 
increase in the rate of sarcopenia (47%) following all 
cancer therapies (chemo-radio-and immunotherapy). 
The direct toxic effects of chemotherapy on skel-
etal muscle metabolism and loss of muscle mass were 
reported in 13.7% of the studies, while studies that 
reported the impact of sarcopenia on a reduction in 
chemotherapy dosage or a delay in the administration 
of chemotherapeutic cycles was 10.8% and 7.8% for the 
administration of immunotherapy. A total of 11.8% of 
studies showed lowered overall survival by the coinciding 
impact of chemotherapy and sarcopenia and 14.7% by 
the coinciding impact of radiotherapy and sarcopenia 
(Tab. 1). Moreover, the outcomes of the reviewed stud-
ies derived from their findings which showed that 93.1% 
reported a significant negative correlation and prognosis 
related to the co-occurrence of sarcopenia and cancer 
therapy (chemo-radio-and immunotherapy) (Tab. 1).
Discussion
Cancer chemotherapy and sarcopenia 
In this study, most of the reviewed studies were 
about the potential impact of cancer chemotherapy 
and sarcopenia. Chemotherapy immensely strains the 
body of malignancy patients, causing a more prominent 
consumption of energy and thus an expansion on the 
whole-cell catabolic cycles that, subsequently, sabotage 
tissue creation [16]. Malignancy is conceivably the most 
remarkable obsessive condition that advances muscle 
atrophy, especially in elderly patients. On the other 
hand, sarcopenia is prevalent in patients with various 
malignancies and the rate of its occurrence in cancer 
patients varies between 11–74%. It has been recog-
nized that cancer patients with sarcopenia have a poor 
prognosis regarding various malignancies, such as lung, 
stomach, pancreas, and colorectal cancers alongside dif-
ferent complications associated with cancer treatment 
[17, 18]. In addition, long-term outcomes and overall 
survival are significantly shorter while death rates are 
more frequently observed in cancer patients with sarco-
penia submitted to oncological therapy [19], as reported 
in studies by Blauwhoff-Buskermolen et al. [20], Liu et 
al. [21], Ma et al. [22], Paireder et al. [23], Järvinen et 
al. [24], Choi et al. [25], Jung et al. [26], Miyamoto et 
al. [27], Derksen et al. [28], Go et al. [29], Prado et al. 
[30] and Rutten et al. [31]. 
There is also a direct toxic effect of chemotherapy on 
skeletal muscle metabolism and loss of muscle mass. This 
was reported in studies by Blauwhoff-Buskermolen et 
al. [20], Awad et al. [32], Yip et al. [33], Daly et al. [34], 
Guinan et al. [35], Cooper et al. [36], Benjamin et al. 
[37], Sandini et al. [38], Poterucha et al. [39], Eriksson 
et al. [40], Nattenmüller et al. [41], Goncalves et al. [42], 
Zargar et al. [43] and Rimar et al. [44]. 
During cancer chemotherapy, there is a progressive loss 
of skeletal muscle mass by 1.4 kg after 9 weeks of chemo-
therapy. In patients receiving systemic chemotherapy 
for colorectal cancer, deficiency of ≥ 9 % muscle mass 
during 3 months was freely prescient of lower survival at 
6 months. This might be related to uncontrolled muscle 
protein catabolism that is exaggerated as the tumour 
growth progresses [20, 45, 46]. As the amount of stored pro-
tein diminishes due to sarcopenia, the metabolism and im-
munity decline relatively to this, prompting an abatement 
in antitumor response and an increase in mortality [47].
Other possible contributing factors to aggressive 
loss of muscle mass secondary to low food intake are 
nausea, vomiting, diarrhoea, anorexia, and fatigue. This 
is induced by many chemotherapeutic agents particularly 
by platinum compounds, such as cisplatin, carboplatin, 
and oxipaltin [48], as also reported by the findings of 
the present study where platinum-based compounds 
represented the most common chemotherapeutic agents 
administered among the reviewed studies within the scope 
of chemotherapy and sarcopenia. Neuropathy and myal-
gia secondary to complications by taxanes chemotherapy 
might induce sarcopenia and skeletal muscle loss [49]. 
Moreover, cancer chemotherapy may also induce oxida-
tive stress in skeletal muscle tissues through increase 
production of reactive oxygen species [50, 51], causing 
a reduction in muscle microvasculature through antian-
giogenesis [52] and increase muscle catabolism secondary 
to the overproduction of tumour growth factors [50, 53]. 
Lower content of muscular fibres alongside 
a concomitant decrease of some metabolizing enzymes 
available in the skeletal muscle tissue could decrease 
the capability to metabolize some chemotherapeutic 
agents. An example of these enzymes is dihydropyrimi-
dine dehydrogenase (DPD), which plays an important 
role in the catabolism of 5-Fluorouracil and capecit-
abine by converting fluoropyrimidines to inactive 
metabolites. On the other hand, patients with low lean 
body mass have poor tolerability and show more toxic 
adverse effects from anticancer drugs. This is related 
to a decreased volume of distribution of these agents 
which may lower the capacity for metabolizing antican-
cer [54]. Such patients are more prone to a reduction in 
chemotherapy dosage or a delay in the administration of 
chemotherapeutic cycles, as reported in studies by Ali 
et al. [54], Palmela et al. [55], Prado et al. [56], Barret et 
al. [57], Jung et al. [26], Kurk et al. [58], Go et al. [29], 
Prado et al. [30], Prado et al. [59], Mazzuca et al. [60], 
and Zargar et al. [43]. 
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Skeletal muscle mass also decreases during neoad-
juvant chemotherapy which might impair the prognosis 
for adjuvant therapy. Accordingly, maintaining muscle 
mass during chemotherapy administration is indepen-
dently associated with disease stabilization and mortality 
reduction [21, 22, 61]. 
Literature reported that several molecular path-
ways have been recognized for muscle protein deg-
radation and skeletal muscle depletion after cancer 
chemotherapy administration, such as dysregulation 
in energy metabolism, mitochondrion biogenesis, and 
dysregulation in muscle fibre metabolism following 
mitochondrial damage and reduced cytochrome C 
synthesis needed for oxidative phosphorylation and 
peroxisome proliferator-activated receptor gamma 
co-activator 1-alpha (PGC-1a) [26]. Mammalian Target 
Of Rapamycin (mTOR) inhibitors, such as everolimus 
and temsirolimus, involved insulin-like growth factor 1/ 
/phosphatidylinositol-3-kinase/PKB–protein kinase B)/ 
/mammalian target of rapamycin pathway in activating 
skeletal muscle synthesis [62]. 
Platinum compounds induced sarcopenia to in-
clude several pathways, such as ubiquitin-proteasome 
pathway (UPP) in the degradation of myofibrillar 
proteins; the autophagy-lysosome pathway (ALP) in 
the elimination of mitochondria, over-expression of 
pro-inflammatory cytokines (TNF-a) leading to the 
activation of the NF-kB pathway, activation of the my-
ostatin pathway, phosphorylation of SMAD2, silences 
the IGF- 1/PI3K/Akt/mTOR anabolic pathway through 
the decreased phosphorylation of Akt and mTOR [63]. 
Doxorubicin and etoposide cause skeletal muscle deple-
tion and muscle protein degradation and direct muscle 
loss through the activation of the NF-kB molecular 
pathway. This leads to up-regulation of ubiquitin and 
proteasomes, increasing the process of proteolysis and 
production of inflammatory cytokines (IL-1b, IL-6, and 
TNF-a) which in turn increase E3 ligases (atrogin-1), 
and the ubiquitin-protein binding for proteolysis [64–66].
Cancer radiotherapy and sarcopenia 
Radiation restrains recovery and muscle hypertro-
phy by harming satellite cells. Radiation is thought to 
forestall satellite cell mitosis by causing breaks in strands 
of the cell’s DNA. If a break happens just on a single 
strand, the harm can be fixed by polymerases utilizing 
the correlative strand as a layout. If harm happens at 
a similar point on the two strands, the deletion may be 
irreparable which can prompt mitotic failure and cell 
death [67]. 
It has been reported that muscle damage and fibrosis 
are common and irreversible late effects of radiation on 
skeletal muscle tissue [68]. Radiotherapy is associated 
with a wide range of toxic effects that could further de-
teriorate the nutritional status of cancer patients, such 
as xerostomia, dysphagia, oral mucositis, oral pain, and 
sticky saliva [69–71]. Simultaneous chemotherapy and 
radiation are related to significant toxicities including 
mucositis, dysphagia, odynophagia, nausea, vomiting, 
anorexia, fatigue, and dysgeusia bringing about eating 
difficulty [72–74]. Lower content of muscular fibres, 
mass and strength are more likely to require radiation 
treatment breaks and suffer chemotherapy toxicity. 
These findings were reported in studies by Ganju et al. 
[73], Li et al. [75] and Panje et al. [76]. 
Moreover, numerous patients present with sympto-
matic tumours that lead to eating difficulty preceding 
the inception of treatment. Patients with HNC going 
through concurrent chemo-radiotherapy are regu-
larly losing more than 5 % of their body weight in the 
6 months around this therapy [77, 78]. To some extent, 
this has been exacerbated by a change in resting energy 
consumption, which assists the loss of lean body mass 
seen during and following treatment. Accordingly, mal-
nutrition might be present nearly in 35-60%, weight loss 
in 10%, and sarcopenia in up to 70% among patients 
undergoing radiotherapy for HNC. Therefore, sarco-
penia is associated with poor overall and disease-free 
survival [79], as presented in studies by Cho et al. [80], 
Mallet et al. [81], van Rijn-Dekker et al. [82], Thureau 
et al. [83], Sanders et al. [84], Shen et al. [85], Olson et 
al. [86], Ma et al. [87], Yoon et al. [88], Liang et al. [89], 
Lee et al. [90], Lin et al. [91], Park et al. [92], Kiyotoki 
et al. [93], and Pielkenrood et al. [94]. 
This expanded radiation-induced toxicity in sarco-
penic patients contrarily impacts their quality of life 
since dysphagia altogether impacts the quality of life 
[95]. Furthermore, an earlier literature review showed 
that sarcopenia itself was related to an undeniable 
decrease in quality of life [96]. A recent study reported 
that sarcopenia is a powerful independent prognostic 
factor, related to an ascent of the general mortality 
in patients treated solely by radio-chemotherapy for 
locally advanced oesophageal cancer. Along these 
lines, the quality of life in this patient population may 
be influenced by both radiation-induced toxicities and 
sarcopenia [81].
Cancer immunotherapy and sarcopenia 
The advancement of immune senescence with age is 
likely a result of many associating cytokine and hormonal 
adjustments. Increased age, muscle loss, and immune 
senescence are believed to be interlinked. Skeletal 
muscle is known to modulate the immune system by 
producing cytokines (myokines) such as interleukin (IL)-
15 and IL-6, and it has been proposed that sarcopenia 
causes a change in cytokine signalling which modifies 
immune cells to induce immune dysregulation and 
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create pro-inflammatory conditions [97–99]. Changes 
in other immune cell populations, such as expanded 
myeloid-derived suppressor cells (MDSCs), that have 
been accounted for with increasing age may likewise 
be connected to skeletal muscle loss through changes 
production of myokines [100, 101]. Chronic inflamma-
tion within malignancy also adds to sarcopenia. For 
instance, a high serum level of IL-6, a pro-inflamma-
tory cytokine adding to muscle catabolism, following 
PD-1 blockade was related to poor response [102, 103]. 
Therefore, combined blockade of IL-6 and PD-1/PD-
L1 signalling exerts synergistic anti-tumour effects 
[104]. Furthermore, restricting T cell infiltration in 
the tumour due to transforming factor-b signalling, an 
immunosuppressive cytokine that additionally adds to 
sarcopenia [105, 106]. On the other hand, peroxisome 
proliferator-initiated receptor-gamma coactivator 
(PGC)-1a is a key factor created in the muscle that 
has fundamental negative impacts on the anti-tumour 
immune response. Along these lines, skeletal muscle 
loss may prompt expanded creation of TGF-b and 
IL-6, and diminished creation of PGC-1a and other 
myokines [107, 108], which might be related to poor 
response to PD-L1 blockade. Hence, sarcopenia has 
been related to poor outcomes or toxicity to tyrosine 
kinase inhibition, and to immune checkpoint inhibitors 
(ICIs), including programmed cells death 1 (PD-1) 
inhibitors, such as nivolumab and pembrolizumab 
[109, 110]. This was evidenced in earlier studies by 
Heidelberger et al. [111], Daly et al. [112], Revel et 
al. [113], Heidelberger et al. [114], Massicotte et al. 
[115], and Veasey-Rodrigues et al. [116]. 
Sorafenib through multiple steps causes inhibi-
tion of PI3K, Akt, and mTOR which are directly 
involved in the activation of amino acid transporters 
and synthesis of muscle protein alongside inhibition 
of the physiologically activated pathways follow-
ing the physical exercise involving RAF, MEK, and 
MAPK/ERK kinase. Moreover, it causes a reduction 
in muscle blood supply and substrates delivery to the 
muscle through antiangiogenesis properties [117]. 
The PD-1 inhibitors, such as nivolumab or pembroli-
zumab, block the PD-1/programmed death-ligand 
1 (PD-L1) pathway by which malignancy cells escape 
immune recognition. Sarcopenic patients treated 
with nivolumab for non-small cell lung carcinoma 
(NSCLC) had more limited progression-free survival 
and overall survival [118]. Moreover, earlier studies 
found a significant relationship between sarcopenia, 
shorter progression-free survival, and lower response 
rate in NSCLC patients treated with PD-1 checkpoint 
inhibitors [110, 119]. A higher incidence of adverse 
events was also reported in sarcopenic melanoma 
patients treated with PD-1 inhibitors [111, 120] and 
ipilimumab [112].
Conclusion
Despite the high proportion of the reviewed studies 
that were retrospectively conducted, it was observed that 
the dual impact from coinciding potential complica-
tions of cancer therapy and sarcopenia are highlighted. 
Consequently, the evaluation of sarcopenia in cancer 
patients should be considered as a primary part of on-
cology care in cancer patients receiving diverse lines of 
cancer therapy. 
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